Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Complete tumour response (pCR) to neo-adjuvant chemo-radiotherapy for rectal cancer is associated with a reduction in local recurrence and improved disease-free and overall survival, but is achieved in only 20-30% of patients. Drug repurposing for anti-cancer treatments is gaining momentum, but the potential of such drugs as adjuncts, to increase tumour response to chemo-radiotherapy in rectal cancer, is only just beginning to be recognised. METHODS: A systematic literature search was conducted and all studies investigating the use of drugs to enhance response to neo-adjuvant radiation in rectal cancer were included. 2137 studies were identified and following review 12 studies were extracted for full text review, 9 studies were included in the final analysis. RESULTS: The use of statins or aspirin during neo-adjuvant therapy was associated with a significantly higher rate of tumour downstaging. Statins were identified as a significant predictor of pCR and aspirin users had a greater 5-year progression-free survival and overall survival. Metformin use was associated with a significantly higher overall and disease-free survival, in a subset of diabetic patients. CONCLUSIONS: Aspirin, metformin and statins are associated with increased downstaging of rectal tumours and thus may have a role as adjuncts to neoadjuvant treatment, highlighting a clear need for prospective randomised controlled trials to determine their true impact on tumour response and overall survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
Kapiteijn, E., Marijnen, C. A. M., Nagtegaal, I. D., Putter, H., Steup, W. H., Wiggers, T., Rutten, H. J. T., Pahlman, L., Glimelius, B., van Krieken, J. H. J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010580 · Cited by 4,205 · cited 1×
“Numerous studies have now demonstrated that neo-adjuvant treatment improves oncological outcomes (Pahlman et al, 1997; Kapiteijn et al, 2001; Rullier et al, 2001; Sauer et al, 2004; Bosset et al, 2006; Peeters et al, 2007).”
BackgroundThe mesorectum in rectal cancer surgery—the clue to pelvic recurrence?
Heald, R. J., Husband, E. M., & Ryall, R. D. H. (1982) · Journal of British Surgery · doi:10.1002/bjs.1800691019 · Cited by 2,917 · cited 1×
“Concerns regarding the high rates of local recurrence of rectal cancer (Heald et al, 1982; Pilipshen et al, 1984; Nymann et al, 1995; den Dulk et al, 2009; Shihab et al, 2010) have catalysed the evolution of operative techniques, to facilitate more ‘radical rectal resections’, (e.g., Total…”
BackgroundChemotherapy with Preoperative Radiotherapy in Rectal Cancer
Bosset, J.-F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., & Ollier, J.-C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060829 · Cited by 2,688
Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer
(1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361402 · Cited by 2,517
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 1×
“G-proteins such as RAS, important in colorectal cancer (Cox et al, 2014), undergo post-translational prenylation and early work suggested that RAS activation could be blocked by targeting this pathway (Schafer et al, 1989).”
BackgroundMesorectal excision for rectal cancer
MacFarlane, J. K., Ryall, R. D. H., & Heald, R. J. (1993) · The Lancet · doi:10.1016/0140-6736(93)90207-w · Cited by 1,781
Rothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351 · cited 1×
“Similarly, long-term vascular studies of regular low-dose aspirin users have highlighted the significant reduction in colorectal cancer rates and mortality (Rothwell et al, 2010).”
BackgroundGreenhough, A., Smartt, H. J. M., Moore, A. E., Roberts, H. R., Williams, A. C., Paraskeva, C., & Kaidi, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp014 · Cited by 1,220 · cited 1×
“This ultimately activates downstream signalling pathways that can increase tumour cell survival, proliferation and migration (Greenhough et al, 2009; Wang and DuBois, 2009).”
BackgroundSelf-citationPeeters, K. C. M. J., Marijnen, C. A. M., Nagtegaal, I. D., Kranenbarg, E. K., Putter, H., Wiggers, T., Rutten, H., Pahlman, L., Glimelius, B., Leer, J. W., et al. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000257358.56863.ce · Cited by 1,191 · cited 1×
“Numerous studies have now demonstrated that neo-adjuvant treatment improves oncological outcomes (Pahlman et al, 1997; Kapiteijn et al, 2001; Rullier et al, 2001; Sauer et al, 2004; Bosset et al, 2006; Peeters et al, 2007).”
BackgroundRothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984 · cited 1×
“…risk has been explored in a number of settings; in particular, for high-risk patients with FAP (Waddell and Loughry, 1983; Giardiello et al, 1993), HNPCC (Burn et al, 2011), patients already treated for colorectal adenomas (Baron et al, 2003), and for colorectal carcinomas (Rothwell et al, 2012).”
Background
Cited by
Immune Cell Membrane‐Coated Biomimetic Nanoparticles for Targeted Cancer Therapy
Oroojalian, F., Beygi, M., Baradaran, B., Mokhtarzadeh, A., & Shahbazi, M. (2021) · Small · doi:10.1002/smll.202006484 · Cited by 528
Campbell, J. M., Bellman, S. M., Stephenson, M. D., & Lisy., K. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.003 · Cited by 455
Weiss, M., Nikisher, B., Haran, H., Tefft, K., Adams, J., & Edwards, J. G. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.06.006 · Cited by 5
Metadata
- Authors
- Gash, K. J., Chambers, A. C., Cotton, D. E., Williams, A. C., & Thomas, M. G.
- Venue
- British Journal of Cancer
- Published
- 2017-06-22
- Volume
- 117
- Issue
- 2
- Pages
- 210-219
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2687677872
- Cited by
- 47
- References
- 10
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.